Group 1 - The company Jiangsu Sihuan Biological Co., Ltd. announced a capital reduction of 150 million yuan for its wholly-owned subsidiary Jiangsu Chenwei Ecological Park Technology Co., Ltd., reducing its registered capital from 400 million yuan to 250 million yuan [1][3] - The decision for the capital reduction was approved during the 16th meeting of the 10th board of directors held on August 25, 2025, and does not constitute a related party transaction or a major asset restructuring, thus not requiring shareholder approval [1][2] - The capital reduction aims to enhance asset management efficiency in line with the company's medium to long-term strategic planning, and it will not adversely affect the company's financial status or operating results [3] Group 2 - Jiangsu Chenwei Ecological Park Technology Co., Ltd. has total assets of approximately 305.86 million yuan and total liabilities of about 72.76 million yuan as of the first half of 2025 [2] - The company reported a net profit of -2.47 million yuan for the first half of 2025, compared to a net profit of -70.31 million yuan for the entire year of 2024 [2] - The subsidiary is not listed as a dishonest executor, indicating a stable legal standing [2]

说明：山东省中船阳光投资发展有限公司、潍坊嘉恒置业有限公司、江苏阳光集团有限公司为原实控人及其附属企业。 法定代表人：邱为碧 主管会计工作的负责人：刘智江 会计机构负责人：徐海珍 江苏四环生物股份有限公司 2025 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 编制单位：江苏四环生物股份有限公司 金额单位：万元 | 非经营性资金 | | 占用方与上市公 | 上市公司核 | 2025 | 年期初占用 | 2025年1-6月占 | 2025年1-6月 | 2025 年 1-6 月偿 | 2025 年 6 月 30 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 占用 | 资金占用方名称 | 司的关联关系 | 算的会计科 目 | 资金余额 | | 用累计发生金 额（不含利息） | 占用资金的 利息(如有) | 还累计发生金额 | 日占用资金余额 | 原因 | 占用性质 | | 控股股东、实际控制人 | | | | | | | | | | | | | 及其附属企业 | | | | ...

江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 5 月 12 日在公 司会议室以现场结合通讯的方式召开了第十届董事会第十二次会议。本公司于 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日在公 司会议室以现场结合通讯的方式召开了第十届董事会第十六次会议。公司于2025 年 8 月 15 日以通讯方式发布了召开董事会的通知。出席会议董事应到 5 名，实 到 5 名，分别为邱为碧、陈龙、韦麟福、刘卫、吴良卫。本次会议符合《公司法》 和《公司章程》有关规定，形成的决议合法、有效。 一、审议通过了《2025 年半年度报告全文及摘要》； 《2025 年半年度报告》详见巨潮资讯网（www.cninfo.com.cn）；《2025 年 半年度报告摘要》详见指定信息披露媒体《证券时报》、《证券日报》、《中国 证券报》和巨潮资讯网。 表决结果：5 票同意，0 票反对，0 票弃权。 股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： * ST 四 环 公 告 编 号 ： 临 - ...

股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： * ST 四 环 公 告 编 号 ： 临 - 2 0 2 5 - 5 2 号 江苏四环生物股份有限公司 关于全资子公司减资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次减资的基本情况 根据管理和发展的实际需要，江苏四环生物股份有限公司（以下简称"公司"） 的全资子公司江苏晨薇生态园科技有限公司（以下简称"晨薇生态园")拟对注 册资本减资 15,000 万元。本次减资后，晨薇生态园注册资本由 40,000 万元减至 25,000 万元，仍为公司的全资子公司。 公司于 2025 年 8 月 25 日召开了第十届董事会第十六次会议，审议通过了《关 于全资子公司江苏晨薇生态园科技有限公司减资的议案》。根据《深圳证券交易 所股票上市规则》、《公司章程》等有关规定，本次交易不构成关联交易，亦不 构成重大资产重组，本次减资事项无需提交公司股东大会审议。 二、本次减资主体的基本情况 公司名称：江苏晨薇生态园科技有限公司 类型：有限责任公司（非自然人投资或控股的法人投资） 法定代表人：冯靖 注册资 ...

江苏四环生物股份有限公司 2025 年半年度报告全文 江苏四环生物股份有限公司 2025 年半年度报告 【2025 年 8 月】 所有董事均已出席了审议本次半年报的董事会会议。 本报告如涉及未来发展计划等前瞻性陈述，该计划不构成公司对投资者 的实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当 理解计划、预测与承诺之间的差异。 公司在经营管理中可能面临的风险及应对措施已在本报告"第三节 管理 层讨论与分析"之"十、公司面临的风险和应对措施"部分予以描述，敬请 投资者关注相关内容。 公司 2024 年度经审计的财务数据触及《深圳证券交易所股票上市规则》 第 9.3.1 条之"（一）最近一个会计年度经审计的利润总额、净利润、扣除 非经常性损益后的净利润三者孰低为负值，且扣除后的营业收入低于 3 亿元" 规定的对股票交易实施退市风险警示的情形，公司股票交易被实施退市风险 警示(股票简称前冠以"*ST"字样)。敬请广大投资者注意风险，谨慎投资。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 1 江苏四环生物股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 837344 | 三元基因 | 30.72 | -3.64% | 2.94万 | 9044.53万 | | 002773 | 康弘药业 | 42.26 | -3.38% | 11.33万 | 4.81亿 | | 430047 | 诺思兰德 | 28.23 | -3.16% | 8.74万 | 2.50亿 | | 833575 | 康乐卫士 | 17.80 | -2.57% | 5.20万 | 9287.66万 | | 000534 | 万泽股份 | 16.90 | -1.74% | 18.96万 | 3.20 Z | | 300841 | 康华生物 | 84.77 | -1.70% | 4.19万 | 3.55亿 | | 600211 | 西藏药业 | 46.04 | -1.62% | 9.87万 | 4.54亿 | | 688163 | 赛伦生物 | 25.23 | -1.60% | 1.79万 | 4519.15万 | | 688293 | 奥 ...

Core Points - Jiangsu Sihuan Biological Co., Ltd. has changed its registered address and revised its Articles of Association, which were approved by the board and shareholders [1][2] - The company has completed the necessary business registration changes and obtained a new business license [1] - The new registered information includes the company name, unified social credit code, type, legal representative, registered capital, establishment date, and new address [1] Company Information - Company Name: Jiangsu Sihuan Biological Co., Ltd. [1] - Unified Social Credit Code: 913202001381477183 [1] - Type: Joint-stock company (listed) [1] - Legal Representative: Qiu Weibing [1] - Registered Capital: 1,029.556222 million RMB [1] - Establishment Date: May 18, 1992 [1] - New Address: 41st Floor, No. 2 Binhai East Road, Jiangyin City [1] Business Scope - The company manufactures large-volume injectables, small-volume injectables (including anti-tumor drugs), tablets (including anti-tumor drugs), hard capsules, syrups, oral solutions, alcohol preparations, raw materials, and traditional Chinese medicine extracts [1] - It also engages in the manufacturing of pharmaceutical intermediates (excluding chemical hazardous products), medical information consulting, technology transfer services, and various manufacturing and sales activities [1]

Core Viewpoint - Jiangsu Sihuan Biological Co., Ltd. has completed the registration of changes in business operations and has obtained a new business license, along with a change in its office address [1] Group 1: Company Information - The company held its 13th meeting of the 10th Board of Directors on June 4, 2025, where it approved the proposal to change the registered address and amend the Articles of Association [1] - The new registered information includes: - Company Name: Jiangsu Sihuan Biological Co., Ltd. - Unified Social Credit Code: 913202001381477183 - Type: Joint-stock Company (Listed) - Legal Representative: Qiu Weibing - Registered Capital: 1,029.556222 million RMB - Establishment Date: May 18, 1992 - Address: 2 Binhai East Road, Building 41, Jiangyin City, Rooms 05 and 06 [1] Group 2: Business Scope - The company's business scope includes the manufacturing of large-volume injectables, small-volume injectables (including anti-tumor drugs), tablets (including anti-tumor drugs), hard capsules, syrups, oral solutions, alcoholic solutions, raw materials, traditional Chinese medicine extraction, and the manufacturing of Class II psychotropic drugs [1] - Additional activities include the packaging of specific health products, pharmaceutical consulting, technology transfer services, and the manufacturing of pharmaceutical intermediates (excluding chemical hazardous products) [1] - The company is also involved in the manufacturing and sales of textiles, chemical products (excluding hazardous products), electronic products, and telecommunications equipment, as well as investment activities and import/export operations related to its products and technologies [1]

股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： * S T 四 环 公 告 编 号 ： 临 - 2025 - 4 9 号 江苏四环生物股份有限公司 关于完成工商变更登记备案并换发营业执照 统一社会信用代码：913202001381477183 类型：股份有限公司（上市） 法定代表人：邱为碧 注册资本：102,955.6222 万人民币 成立日期：1992 年 5 月 18 日 住所：江阴市滨江东路 2 号 41 楼 05、06 座 暨变更办公地址的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 6 月 4 日召开 了第十届董事会第十三次会议，审议通过了《关于变更注册地址并修订<公司章 程>的议案》（公告编号：临-2025-38 号），上述议案已经 2025 年第三次临时 股东会审议通过（公告编号：临-2025-46 号）。 近日，公司已完成了相关工商变更登记和章程备案手续，并取得了新的《营 业执照》，公司变更后的注册信息如下： 公司名称：江苏四环生物股份有限公司 股 票 代 码 ...

Core Viewpoint - Jiangsu Sihuan Bioengineering Co., Ltd. (referred to as "Sihuan Bio" or "*ST Sihuan") expects to increase revenue without profit in the first half of 2025, projecting revenue of approximately 180 million to 190 million yuan, a year-on-year increase of 70.12% to 79.57%, while net profit attributable to shareholders is expected to be a loss of 9 million to 13 million yuan, widening from a loss of 11.0581 million yuan in the same period last year [1][2]. Group 1: Financial Performance - Sihuan Bio's revenue is projected to grow significantly due to bulk sales of seedlings by its wholly-owned subsidiary, Jiangsu Chenwei Ecological Park Technology Co., Ltd., despite a slight decline in revenue from its main subsidiary, Beijing Sihuan Bio-Pharmaceutical Co., Ltd. [2] - The company has reported continuous losses for four consecutive years, with revenues of 351 million yuan, 270 million yuan, 235 million yuan, and 204 million yuan from 2021 to 2024, and corresponding losses of 34.79 million yuan, 48.79 million yuan, 75.27 million yuan, and 110 million yuan [6][8]. Group 2: Legal and Regulatory Issues - Sihuan Bio is facing ongoing financial burdens due to securities false statement liability disputes, with 188 investors filing lawsuits against the company, totaling 41.2075 million yuan in claims [3]. - The company has been penalized by the China Securities Regulatory Commission (CSRC) for false disclosures regarding its actual controller, leading to administrative penalties and market bans for the former actual controller, Lu Keping [4][5]. Group 3: Market Challenges - The company is experiencing significant sales pressure due to intensified competition and price reductions in the pharmaceutical industry, particularly in the context of centralized drug procurement [7][8]. - Despite an increase in research and development (R&D) personnel and investment, the company’s core pharmaceutical business has not shown substantial improvement, relying instead on non-core business revenue for short-term gains [8].